Cellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update
November 02, 2015 at 08:33 AM EST
Cellectar Biosciences, Inc. (NASDAQ: CLRB), an oncology-focused biotechnology company, today provides an update on its recently ...